65,437 trials
Stage I Prostate Cancer · Stage IIA Prostate Cancer · Stage IIB Prostate Cancer
Primary: Adverse Events Assessed Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 — 0; 0; 0; 0 Participants
Pleomorphic Adenoma of the Parotid · Warthin Tumor · Head and Neck Disorder
Primary: Facial Nerve Correlation of Fluorescein Sodium With Electrostimulation — 3.8 score on a scale
Obesity
Primary: Percent of Participants Who Achieve Clinically Significant Weight Loss of at Least 5 Percent of Baseline Weight at 26 Weeks — 40; 43; 48; 32 Participants
Colorectal Cancer
Primary: Migration — 2 Participants
Aging · Cognitive Function Abnormal · Cognitive Performance
Primary: Self-Perceived Need for Cognitive Training — 7.49; 3.34 score on a scale
Asthma
Primary: FeNO — 14.3; 34.3; 36.0; 49 parts per billion — p=<0.1
Childhood Obesity
Primary: Change in BMI for Pediatric Participants — -0.7; -0.9 BMI (weight in kg/height in m^2)
Parenting · Well-Being, Psychological · Mental Health Wellness 1
Primary: Parenting Behavior Inventory - Very Short Form — 3.42; 3.36 Units on a Scale
Parkinson Disease
Primary: Usability and Acceptability Questionnaire (UAQ) — 4.86 Score on a scale
Obesity
Primary: Weight Change — -2.50; -0.51 percentage of body weight — p=0.008
Bruxism · Sleep Bruxism, Adult · Awake Bruxism
Primary: Pain Intensity Measured by Visual Analog Scale (VAS) — 8.909; 8.957; 9.167; 1.591 VAS score (0-10)
Psychotic Disorders
Primary: Auditory Hallucination Rating Scale (AHRS) — 30.00; 24.33; 26.82; 20.89 AHRS total score
Suicide · Accidental Injuries · Firearm Injury
Primary: Feasibility of the Intervention — 18; 40 Participants
Mechanical Ventilation · Airway Patency · Respiratory Depression
Primary: Inspiratory Airflow — 0.36; 0.47; 0.44 L/s
Chronic Inducible Urticaria
Primary: Safety and Tolerability — 3; 7 Participants with a TEAE